Atebimetinib Data Show Weight Preservation Doubles Survival in Pancreatic Cancer
IMRX is trading near its 52-week low of $3.86 (13% above the low).
Summary
Immuneering presented new Phase 2a analyses at AACR 2026 showing atebimetinib + mGnP patients were twice as likely to maintain or gain weight versus a benchmark, and weight-stable patients had significantly longer overall survival (HR=3.13, p=0.049). The data also suggest tumor reduction presence, not depth, drives survival benefit. This supports the dual mechanism (tumor shrinkage + cachexia counteraction) behind the 17.3-month median OS reported at ASCO 2026. The ongoing Phase 3 MAPKeeper 301 trial is actively enrolling first-line pancreatic cancer patients, making this a key validation readout for the registrational program.
At the time of this announcement, IMRX was trading at $4.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $276.3M. The 52-week trading range was $3.86 to $9.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.